Medical Bulletin 27/November/2021

Daye Diana Choi and colleagues discovered that both general and abdominal obesity increased the incidence of cranial nerve palsies (CNP) in a retrospective cohort analysis. Furthermore, a combination of general and abdominal obesity may raise the risk of CNP. The purpose of this study was to look at the relationship between obesity and the development of third, fourth, and sixth cranial nerve palsies (CNP).

The findings of this study were published in the American Journal of ophthalmology on 17th September 2021.

For more details, check out the full story on the link below:

Obesity Increases Risk Of Cranial Nerve Palsies: Study

Bentracimab, an intravenous reversal agent for ticagrelor, has shown immediate and sustained reversal of the Tiacgrelor's antiplatelet effects in both patients undergoing surgery and those with major bleeding, according to a prespecified interim analysis of the REVERSE-IT study presented this week at AHA, 2021.

The drug is a recombinant IgG1 monoclonal antibody fragment that binds to both ticagrelor and its major active circulating metabolite, reversing the antiplatelet effects within 5 minutes. Previous phase I data in healthy participants, published in 2019, sparked excitement as a potential answer to the challenges faced not just by surgeons, but also by physicians when patients on ticagrelor present with an intracranial hemorrhage, for example, and can't wait the recommended 5 days for the drug's effects to wear off.

For more details, check out the full story on the link below:

AHA 2021: Bentracimab Rapid And Safe To Reverse Ticagrelor's Effects, REVERSE IT Study